BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21080343)

  • 1. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
    Grieco P; Franco R; Bozzuto G; Toccacieli L; Sgambato A; Marra M; Zappavigna S; Migaldi M; Rossi G; Striano S; Marra L; Gallo L; Cittadini A; Botti G; Novellino E; Molinari A; Budillon A; Caraglia M
    J Cell Biochem; 2011 Jan; 112(1):341-53. PubMed ID: 21080343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans.
    Federico A; Zappavigna S; Romano M; Grieco P; Luce A; Marra M; Gravina AG; Stiuso P; D'Armiento FP; Vitale G; Tuccillo C; Novellino E; Loguercio C; Caraglia M
    Eur J Clin Invest; 2014; 44(3):285-94. PubMed ID: 24372535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
    Das S; Roth CP; Wasson LM; Vishwanatha JK
    Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma.
    Collett GP; Betts AM; Johnson MI; Pulimood AB; Cook S; Neal DE; Robson CN
    Clin Cancer Res; 2000 Aug; 6(8):3241-8. PubMed ID: 10955810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
    Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
    Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
    Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liprin-alpha2 gene, protein tyrosine phosphatase LAR interacting protein related gene, is downregulated by androgens in the human prostate cancer cell line LNCaP.
    Fujinami K; Uemura H; Ishiguro H; Kubota Y
    Int J Mol Med; 2002 Aug; 10(2):173-6. PubMed ID: 12119554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ILK as a potential marker gene to ascertain specific adenocarcinoma cell mRNA isolation from frozen prostate biopsy tissue sections.
    Kieffer N; Schmitz M; Plançon S; Margue C; Huselstein F; Grignard G; Dippel W; Nathan M; Giacchi S; Scheiden R
    Int J Oncol; 2005 Jun; 26(6):1549-58. PubMed ID: 15870868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
    Singh S; Singh UP; Stiles JK; Grizzle WE; Lillard JW
    Clin Cancer Res; 2004 Dec; 10(24):8743-50. PubMed ID: 15623660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
    Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
    Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.
    Sgambato A; De Paola B; Migaldi M; Di Salvatore M; Rettino A; Rossi G; Faraglia B; Boninsegna A; Maiorana A; Cittadini A
    J Cell Physiol; 2007 Nov; 213(2):528-39. PubMed ID: 17516554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension?
    Cindolo L; Franco R; Cantile M; Schiavo G; Liguori G; Chiodini P; Salzano L; Autorino R; Di Blasi A; Falsaperla M; Feudale E; Botti G; Gallo A; Cillo C
    Eur Urol; 2007 Nov; 52(5):1365-73. PubMed ID: 17126478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
    He D; Falany CN
    Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP.
    Young CY; Montgomery BT; Andrews PE; Qui SD; Bilhartz DL; Tindall DJ
    Cancer Res; 1991 Jul; 51(14):3748-52. PubMed ID: 1712248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
    Zhigang Z; Wenlu S
    Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CCL5 (RANTES) and CCR5 in prostate cancer.
    Vaday GG; Peehl DM; Kadam PA; Lawrence DM
    Prostate; 2006 Feb; 66(2):124-34. PubMed ID: 16161154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
    Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
    Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.